MLTX DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - MLTX

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the MoonLake Immunotherapeutics securities class action is from March 10, 2024, to September 29, 2025 [1]. - Investors who purchased common stock during this period may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 15, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake Immunotherapeutics made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically BIMZELX [5]. - Key points of contention include claims about the molecular targets and clinical benefits of SLK, which were allegedly overstated, leading to investor damages when the truth was revealed [5].